Trial · NCT01268527
Results by group160
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 160
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8 | 0.03% E6201 Gel | -92.9 | 95% Confidence Interval -200.1 to 14.3 | um | |
| Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8 | 0.05% E6201 Gel | -190.3 | 95% Confidence Interval -243.6 to -136.9 | um | |
| Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8 | 0.1% E6201 Gel | -108.0 | 95% Confidence Interval -162.9 to -53.1 | um | |
| Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8 | 0.2% E6201 Gel | -102.7 | 95% Confidence Interval -172.6 to -32.9 | um | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | Daivonex (Calcipotriene Cream) | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | E6201 Vehicle | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.005% E6201 Gel | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.01% E6201 Gel | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.03% E6201 Gel | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.05% E6201 Gel | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.1% E6201 Gel | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.2% E6201 Gel | Worsened | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | Daivonex (Calcipotriene Cream) | Unchanged (no effect) | 6.7 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | E6201 Vehicle | Unchanged (no effect) | 90.0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.005% E6201 Gel | Unchanged (no effect) | 20.0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.01% E6201 Gel | Unchanged (no effect) | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.03% E6201 Gel | Unchanged (no effect) | 6.7 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.05% E6201 Gel | Unchanged (no effect) | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.1% E6201 Gel | Unchanged (no effect) | 0 | Percentage of participants | |
| Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation | 0.2% E6201 Gel | Unchanged (no effect) | 0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01268527/results?page=2